If you live with an autoimmune condition or care for someone who does, you have probably come across the phrase “stem cell therapy” at some point, often attached to claims that range from cautiously hopeful to wildly overblown. What is harder to find is a clear, honest account of what researchers are actually studying, what phase that work is in, and what patients should realistically understand before bringing any of it to their physician. This guide fills that gap. It explains the immunobiology behind why scientists are interested in adipose-derived stem cells for immune-related conditions, which specific condition areas have registered clinical trials, and what the current evidence does and does not support.
TLDR: Adipose-derived stem cells (ADSCs) are being studied in early-phase clinical research for select autoimmune and immune-mediated conditions, based on observed immunomodulatory properties including T-cell suppression and low immunogenicity. No ADSC product holds FDA approval for any autoimmune condition in the United States. The science is active and genuinely interesting, but it is early. This guide explains what that means in practice and what patients need to know before making any decisions.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease or medical condition. Adipose tissue banking is a preservation service for potential future opportunities, not a therapeutic product. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content here is for educational and informational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions. Outcomes of any regenerative medicine research or future therapies are highly individual and cannot be predicted or guaranteed.
Autoimmune conditions are among the most complex and personally disruptive categories of disease. They span an enormous range of presentations, from inflammatory arthritis and inflammatory bowel disease to rare autoimmune lung complications and systemic conditions that affect multiple organs simultaneously. What they share is a common feature: the immune system is responding in a way that is causing harm to the body’s own tissues rather than protecting them. For people living with these conditions, the limitations of current treatments make understanding every avenue of ongoing research feel genuinely important.
That context is also why the autoimmune space has attracted more than its share of misleading marketing. A condition population that is large, often underserved by existing therapies, and motivated to understand emerging science is, unfortunately, a population that unscrupulous clinics target with unapproved products and unverifiable claims. Getting honest, sourced information about what researchers are actually studying, versus what clinics are selling, is not a minor distinction. It is the difference between making an informed decision and being misled into spending significant money on something with no scientific accountability.
This guide covers the legitimate science. It explains what properties of adipose-derived mesenchymal stem cells have attracted researchers working in immunology, which specific condition areas have registered clinical trials, what phase that research is in, and how the European regulatory precedent for one ADSC product fits into the larger picture for US patients. By the end, you will have the vocabulary and context to have a more informed conversation with your physician about what this research means, if anything, for your specific situation.
Why Researchers Are Interested in ADSCs for Immune-Related Conditions
The Immunobiology Basics
Autoimmune conditions arise when the immune system’s regulation breaks down in a way that directs immune responses against the body’s own tissues. The mechanisms vary significantly by condition, but a common thread in many of them is dysregulated T-cell activity, disrupted cytokine signaling, or inadequate immune tolerance. Existing therapies for autoimmune conditions largely work by broadly suppressing the immune system or by targeting specific inflammatory molecules. These approaches are effective for many patients but not for all, and they carry their own risks.
Researchers have observed that ADSCs display immunomodulatory properties in laboratory settings and in early clinical studies, meaning they appear to influence how the immune system responds rather than simply suppressing it. Immunomodulation means the capacity of a cell or substance to regulate or modify immune activity, not necessarily to shut it down entirely, but to shift the balance of how immune responses are initiated, amplified, or resolved.
ADSCs are classified as multipotent mesenchymal stromal cells. The scientific criteria used to identify them internationally, established by the International Society for Cell and Gene Therapy (Dominici et al., 2006), include specific surface marker profiles and differentiation capacity. Their immunomodulatory properties were identified later and have become the primary reason they are being studied in autoimmune research contexts.
Key Properties Under Investigation
The table below summarizes the specific ADSC properties that researchers are investigating in the context of immune-related conditions. Every row describes an observed or hypothesized mechanism in laboratory or early clinical settings. None of these mechanisms have been confirmed as effective for any FDA-approved indication, and more research is needed before any conclusions can be drawn about clinical benefit in humans.
| ADSC Property | What It Means | Why Researchers Are Studying It in Autoimmune Contexts |
|---|---|---|
| T-cell suppression | ADSCs may inhibit the proliferation and activation of T cells, which drive many autoimmune responses | T-cell overactivity is central to conditions like GvHD, RA, and SLE; researchers are exploring whether ADSC secretion can modulate this activity |
| Low MHC II expression (low immunogenicity) | ADSCs express low levels of MHC class II surface markers, which are the molecular flags that trigger immune rejection of foreign cells | This property makes ADSCs candidates for allogeneic (donor-to-patient) research, where immune rejection of donor cells is a primary concern |
| Paracrine signaling | ADSCs secrete cytokines, growth factors, and extracellular vesicles that may influence surrounding immune cell behavior | Paracrine effects can alter the inflammatory environment without requiring the cells to persist long-term, which may be relevant in immune-mediated tissue injury |
| Dendritic cell modulation | ADSCs may suppress maturation and activation of dendritic cells, which initiate and regulate immune responses | Dendritic cells are early-stage immune orchestrators; modulating them could potentially affect downstream inflammatory cascades in research settings |
| Anti-inflammatory cytokine secretion | ADSCs release molecules including IL-10 and TGF-beta that may dampen overactive immune responses in research settings | These molecules have established anti-inflammatory roles; their secretion by ADSCs is a key part of why the secretome is studied in immune contexts |
These properties are under active scientific investigation. No ADSC mechanism has been confirmed as effective for any autoimmune condition through an FDA-approved product. Research findings in laboratory and preclinical settings do not automatically translate into clinical benefit in humans.
What Low Immunogenicity Means and Why It Matters for Allogeneic Research
Immunogenicity refers to the likelihood that a foreign substance introduced into the body will trigger an immune response against it. For cell-based therapies, this is a central challenge: when cells from a donor are transplanted into a recipient, the recipient’s immune system may identify them as foreign and mount a response that destroys them or causes harm.
Most donor-to-patient (allogeneic) cell therapies carry this risk. The surface markers that the immune system uses to distinguish self from non-self, particularly MHC class II molecules, are expressed at high levels on many cell types and trigger immune recognition of donor material. ADSCs express low levels of MHC class II compared to other cell populations, which is one of the reasons they have attracted research interest for allogeneic applications. In preclinical models and early clinical studies, this property appears to reduce (though not eliminate) the risk of immune rejection when donor-sourced ADSCs are used.
This distinction between autologous (using the patient’s own cells) and allogeneic (using donor cells) has significant implications for how these products are developed, regulated, and studied.
| Factor | Autologous ADSC Research | Allogeneic ADSC Research |
|---|---|---|
| Definition | Uses cells collected from the patient receiving treatment | Uses cells from a separate donor individual |
| Source of Cells | Patient’s own adipose tissue | Banked donor adipose tissue, manufactured into a standardized product |
| Regulatory Considerations | Potentially simpler if minimally manipulated; more complex if processed as a Section 351 biologic | Generally regulated as a Section 351 biologic requiring IND and BLA; higher manufacturing standards |
| Examples in Autoimmune Research | NCT02741362 (RA/SLE autologous trial) | NCT06636032 (ALLOFIST, allogeneic Crohn’s fistula); NCT03091993 (allogeneic GvHD) |
| Key Considerations for Patients | Requires a tissue collection procedure from the patient; immune rejection not a primary concern | No collection procedure for the patient; allogeneic product consistency may improve scalability |
Allogeneic ADSC products intended for treating immune conditions are generally regulated by the FDA as Section 351 biologics, requiring both an Investigational New Drug application and, ultimately, a Biologics License Application for marketing approval. No allogeneic ADSC product currently holds FDA marketing approval for any autoimmune condition in the United States. For a broader explanation of the FDA regulatory framework for adipose-derived products, the guide to FDA regulations for adipose tissue provides detailed context.
Condition Areas Where ADSC Research Is Active
The following condition areas have registered clinical trials on ClinicalTrials.gov studying adipose-derived stem cells or closely related products. Registration on ClinicalTrials.gov is a federal transparency requirement. It is not evidence that a product is safe or effective, does not indicate FDA approval, and does not mean patients should seek enrollment without physician guidance.
| Condition Area | NCT Number | Phase | Cell Source | Primary Research Question |
|---|---|---|---|---|
| Graft-Versus-Host Disease (GvHD) | NCT03091993 | Phase I/II | Allogeneic AD-MSCs | Safety and preliminary efficacy in steroid-refractory acute GvHD |
| Crohn’s Perianal Fistula | NCT06636032 (ALLOFIST) | Phase I/II | Allogeneic ADSC (CellReady) | Dose escalation for complex perianal fistulas after conventional treatment failure |
| Crohn’s Disease (systemic) | NCT07010926 | Phase II RCT | Adipose-derived MSC product (L2-01) | Safety and efficacy via IV infusion versus placebo |
| Connective Tissue Disease-Associated ILD | NCT06574581 | Phase I/IIa | Allogeneic AD-MSCs | Safety and feasibility of IV infusion for refractory or rapidly progressive ILD |
| Rheumatoid Arthritis and SLE | NCT02741362 | Phase I/II | Autologous ADSCs | Safety and efficacy in refractory RA and relapsing SLE |
All trials listed above are investigational. No ADSC product has FDA approval for treating any of these conditions. ClinicalTrials.gov registration does not indicate that a product is proven safe or effective.
Graft-Versus-Host Disease
Graft-versus-host disease (GvHD) is a serious complication that can arise after allogeneic hematopoietic stem cell transplants, where donor immune cells recognize the recipient’s tissues as foreign and mount an attack. FDA-approved treatments for GvHD include ruxolitinib and belumosudil for steroid-refractory chronic GvHD. Researchers are investigating whether ADSC-based products may offer additional options in refractory cases where approved therapies have not provided adequate relief. The registered trial NCT03091993 is studying allogeneic AD-MSCs in steroid-refractory acute GvHD with safety and preliminary efficacy as its primary research questions. This is early-phase research, and the results are investigational.
Crohn’s Disease
Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract where the immune system drives ongoing intestinal inflammation that current biologics do not achieve durable remission for in all patients. ADSC research for Crohn’s perianal fistulas has the longest history of any autoimmune application: the completed ADMIRE-CD trial investigated a product called Cx601 (darvadstrocel, later marketed as Alofisel), which received conditional marketing authorization from the European Medicines Agency (EMA) in 2018 for complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease. That authorization is from the EMA, not the FDA, and no equivalent FDA approval exists for this indication in the United States. The registered trials NCT06636032 and NCT07010926 represent ongoing investigation of ADSC products for both perianal and systemic Crohn’s disease, and both are investigational.
Connective Tissue Disease-Associated Interstitial Lung Disease
Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a serious autoimmune complication where immune-mediated inflammation affects lung tissue, and it can be rapidly progressive in some patients. Current treatment options are limited, and researchers are exploring early-phase safety research to determine whether ADSC infusion is feasible and tolerable in this population. The trial NCT06574581 is a Phase I/IIa study investigating the safety of allogeneic AD-MSC IV infusion in refractory or rapidly progressive CTD-ILD. This is a very early stage of investigation focused primarily on safety, not effectiveness.
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are systemic autoimmune conditions with complex treatment landscapes that include biologics, disease-modifying drugs, and immunosuppressants. ADSC research for these conditions remains early-phase and investigational. The registered trial NCT02741362 is investigating autologous ADSCs in patients with refractory RA and relapsing SLE, with safety and efficacy as primary endpoints. This autologous design requires the patient to provide their own tissue as the starting material, making it structurally different from the allogeneic trials described above.
What Phase Is This Research In, and Why That Matters
Most ADSC autoimmune research in the United States is currently in Phase I or early Phase II. Understanding what that means protects patients from misinterpreting trial registration as evidence of effectiveness.
| Research Maturity Level | What It Means | Where ADSC Autoimmune Research Currently Sits |
|---|---|---|
| Preclinical (lab and animal studies) | Hypothesis-generating; not human evidence | Foundation for most ADSC immune research |
| Phase I | Is it safe? What is the dose range? | Multiple ADSC autoimmune trials currently at this stage |
| Phase II | Does it show early signals of working? | A few ADSC autoimmune trials at this stage; results are preliminary |
| Phase III | Confirms effectiveness versus standard care in large randomized studies | Very limited for ADSC autoimmune applications in the US |
| FDA Approval | Product proven safe and effective for a specific indication through a full BLA | No ADSC product approved for any autoimmune condition in the US |
One European regulatory development is worth understanding accurately. In 2018, the European Medicines Agency (EMA) granted conditional marketing authorization to Alofisel (darvadstrocel, the product formerly called Cx601) for complex perianal fistulas in adult Crohn’s disease patients meeting specific criteria, including inadequate response to at least one conventional or biologic therapy. This is an EMA authorization, not FDA approval, and it applies in Europe, not the United States. It is referenced here as educational context: it illustrates what a completed ADSC development pathway has looked like in one application, in one regulatory jurisdiction. It does not mean equivalent FDA approvals are imminent, and it does not represent evidence that ADSC therapies work for autoimmune conditions broadly. The path from that European authorization to a potential US approval involves independent FDA review, a full BLA submission, and clinical trial evidence meeting FDA standards.
How This Research Differs From What Clinics Market Directly to Patients
The clinical research described in this article is meaningfully different from what many patients encounter when they search online or visit a clinic offering “stem cell therapy” for autoimmune conditions. The differences are structural and regulatory, not just a matter of degree.
| Feature | Legitimate Clinical Trial Research | Unregulated Clinic Offering |
|---|---|---|
| Registration | Registered on ClinicalTrials.gov with an NCT number | No verifiable registration |
| Oversight | Reviewed by an Institutional Review Board (IRB) | No independent oversight |
| Cost to patient | Investigational product provided at no charge to participants | Patients typically charged large out-of-pocket fees |
| Eligibility and consent | Strict eligibility criteria and a formal informed consent process | No structured screening or consent process |
| Safety monitoring | Adverse events monitored and reported to the FDA | No structured safety monitoring or reporting |
| Sponsor accountability | Sponsored by academic institutions, hospitals, or companies operating under an IND | Sponsored by a clinic with no IND or regulatory accountability |
| Scientific accountability | Results submitted for peer review and publication | No publication requirement |
The FDA has taken enforcement action against clinics marketing unapproved adipose-derived cell products, including for immune-related conditions. Patients considering any clinic-based offering that claims to treat an autoimmune condition with stem cells should verify whether the product has an active IND, whether the trial is registered, and whether the FDA has issued guidance relevant to that product category. The guide to identifying unethical stem cell practices provides a practical checklist. For context on what legitimate clinical trial participation looks like, see what clinical trials for regenerative medicine involve.
What Patients With Autoimmune Conditions Should Know About Tissue Banking
Save My Fat is a tissue banking and cryopreservation service. It is not a clinical trial operator, a treatment provider, or a path around FDA regulation. It does not enroll patients in trials, provide investigational products, or make any determination about a patient’s eligibility for any research program.
The direct question many patients with autoimmune conditions ask is whether banking their adipose tissue today would help if an ADSC-based therapy eventually becomes available. The accurate answer has several layers.
Banking preserves adipose tissue at its current biological state. The scientific interest in ADSCs for immune-related conditions is a legitimate reason some individuals consider banking, because if future FDA-regulated pathways emerge that require autologous adipose tissue as starting material, having preserved that tissue at an earlier biological age may be relevant to eligibility or to cell quality. That connection is scientifically grounded but speculative about future trial and product designs.
There are also important qualifications specific to autoimmune research. Many of the currently active trials in this space use allogeneic products from donor sources, not the patient’s own tissue. In those cases, previously banked autologous tissue would not be applicable to that specific trial’s design. Each trial’s eligibility criteria and manufacturing requirements are distinct. Additionally, patients with active autoimmune conditions or who are currently on immunosuppressive medications may face additional screening considerations in any trial that involves a tissue collection procedure. These are factors to discuss with a treating physician before making any decisions about banking.
Save My Fat helps individuals preserve their own adipose tissue through validated cryopreservation protocols for potential future opportunities that may arise as regenerative medicine science and FDA regulations evolve. Banked tissue does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program.
For a detailed explanation of what the banking process involves, see the complete guide to adipose tissue banking and the step-by-step explanation of how stem cell banking works. For patients exploring access pathways outside of formal trial enrollment, the guide to Expanded Access programs describes the compassionate use framework in detail. The Reagan-Udall Expanded Access Navigator is a free, independent tool for patients and physicians exploring those pathways.
Frequently Asked Questions
Why are researchers interested in adipose-derived stem cells for autoimmune conditions?
Researchers are investigating ADSCs in autoimmune contexts because of a combination of observed properties: ADSCs appear to suppress T-cell activation and proliferation in laboratory settings, release anti-inflammatory cytokines including IL-10 and TGF-beta, and express low levels of MHC class II surface markers that may reduce the risk of immune rejection in allogeneic applications. These properties make them scientifically interesting for conditions where overactive or dysregulated immune responses drive tissue damage. All of this research is investigational, and no ADSC product has been proven effective for any autoimmune condition in an FDA-approved context. For background on what ADSCs are and how they communicate with surrounding cells, see the patient’s guide to adipose-derived stem cells.
What does immunomodulation mean and how does it relate to ADSCs?
Immunomodulation means the ability of a cell or substance to regulate or modify how the immune system responds, not necessarily by shutting it down, but by influencing the balance of immune activity. ADSCs are being studied for immunomodulatory properties including suppression of T-cell proliferation, inhibition of dendritic cell maturation, and secretion of anti-inflammatory molecules. These effects have been observed in laboratory and preclinical settings. Whether they translate reliably into clinical benefit in humans for specific autoimmune conditions remains under investigation.
What is T-cell suppression and why does it matter in autoimmune research?
T cells are a type of white blood cell that plays a central role in adaptive immune responses, including the immune attacks on self-tissue that characterize many autoimmune conditions. In laboratory settings, ADSCs have been observed to inhibit T-cell proliferation and reduce T-cell activation through paracrine signaling, particularly through molecules like IDO, PGE-2, and TGF-beta. This property is one of the main reasons ADSCs are being studied in conditions like GvHD, RA, and SLE, where excessive T-cell activity is part of the disease mechanism. This research is investigational; T-cell suppression in a lab dish does not automatically produce clinical benefit in a human patient.
What does low immunogenicity mean for adipose-derived cells?
Immunogenicity refers to how likely a foreign substance is to trigger an immune rejection response when introduced into the body. ADSCs express low levels of MHC class II surface markers, which are molecular signals that the immune system uses to recognize and reject donor cells. This means ADSCs may be less likely than other cell types to trigger immune rejection when used in allogeneic (donor-to-patient) applications. This property is one reason ADSCs have attracted research interest for allogeneic products: they may allow a standardized, pre-manufactured product to be used across patients without the same level of immune rejection risk as other cell types, though this has not been confirmed as completely risk-free.
Are there real clinical trials studying ADSCs for autoimmune conditions?
Yes. Multiple registered trials on ClinicalTrials.gov are investigating ADSC-based products for conditions including graft-versus-host disease (NCT03091993), Crohn’s perianal fistula (NCT06636032), Crohn’s disease via IV infusion (NCT07010926), connective tissue disease-associated interstitial lung disease (NCT06574581), and refractory rheumatoid arthritis and SLE (NCT02741362). Registration on ClinicalTrials.gov is a transparency requirement; it does not indicate that a product is proven safe or effective, and it does not mean patients should seek enrollment without consulting their physician first.
What conditions have the most ADSC autoimmune research activity?
Crohn’s disease, particularly perianal fistula complications, has the longest history of ADSC research activity and is the only autoimmune application for which an adipose-derived MSC product has received any marketing authorization anywhere (Alofisel, via the EMA in Europe, not the FDA in the United States). Graft-versus-host disease represents another active area, with several registered trials over multiple years. Research in RA, SLE, and connective tissue disease-associated lung disease is earlier and less mature by volume of published evidence. For a broader view of where ADSC research is most active, the emerging research section provides ongoing updates.
What phase is the ADSC autoimmune research currently in?
Most ADSC autoimmune research in the United States is currently in Phase I or early Phase II, meaning researchers are still primarily studying safety, dose ranges, and early signals of biological activity rather than confirming effectiveness at scale. Phase III trials for ADSC autoimmune applications are very limited in the US context. Phase I and II findings are investigational and preliminary; they do not establish that a treatment works, and they are not a basis for clinical use outside of a registered trial.
Does any ADSC product have FDA approval for any autoimmune condition?
No. As of April 2026, no adipose-derived stem cell product holds FDA approval for any autoimmune condition in the United States. The EMA authorization for Alofisel (darvadstrocel) in Europe for Crohn’s perianal fistula is a separate regulatory jurisdiction and does not constitute FDA approval. Patients should treat any clinic claim of FDA approval for an ADSC autoimmune product with significant skepticism and verify directly with the FDA’s database of approved products.
How is this research different from what clinics are marketing as stem cell therapy?
Legitimate clinical research is registered on ClinicalTrials.gov with an NCT number, reviewed by an IRB, conducted under an IND, provides the investigational product at no charge to participants, and requires a formal informed consent process with structured safety monitoring and adverse event reporting. Unregulated clinic offerings typically lack all of these features, charge patients large out-of-pocket fees for unapproved products, have no independent oversight, and create no requirement for safety monitoring or scientific accountability. The structural differences are not minor. Patients should ask any clinic offering stem cell therapy for an autoimmune condition to provide its NCT number, IND number, and IRB approval documentation before proceeding.
Does banking adipose tissue today help if I have an autoimmune condition?
Banking preserves your adipose tissue at its current biological state for potential future use if FDA-regulated pathways emerge that are compatible with previously banked autologous material. However, many of the active ADSC autoimmune trials use allogeneic (donor-sourced) products, which would not use a patient’s banked tissue. Patients with active autoimmune conditions or who are on immunosuppressive medications may also face additional considerations in any trial requiring a tissue collection procedure. Banking does not guarantee eligibility for any current or future trial. The decision to bank is about preserving optionality in an uncertain future, and it should be discussed with a treating physician who understands your specific clinical situation.
Key Takeaways
- ADSC immunobiology is scientifically grounded but early-stage. ADSCs display immunomodulatory properties in laboratory and preclinical settings, including T-cell suppression, low immunogenicity, and anti-inflammatory cytokine secretion. These properties are under active investigation, not established as clinically effective.
- Specific properties make ADSCs interesting for allogeneic research. Low MHC II expression reduces immune rejection risk in donor-to-patient applications. This has driven development of standardized allogeneic ADSC products for conditions including Crohn’s disease and GvHD.
- Multiple condition areas have registered trials. GvHD, Crohn’s disease (perianal and systemic), connective tissue disease-ILD, RA, and SLE all have registered Phase I or Phase II trials on ClinicalTrials.gov. This is real scientific activity, and it is early-stage.
- The EMA Alofisel authorization is European, not FDA approval. The 2018 conditional marketing authorization for darvadstrocel in Europe for Crohn’s perianal fistula represents one completed ADSC development pathway. It does not mean FDA approval exists or is forthcoming for any ADSC product in the United States.
- Most US ADSC autoimmune research is Phase I or early Phase II. Evidence is preliminary. Positive early-phase findings are not proof of effectiveness and should not be treated as a basis for clinical use outside of a registered trial.
- Legitimate research and clinic offerings are structurally different. Registered trials have IRB oversight, IND authorization, no patient charge for the investigational product, formal safety monitoring, and publication accountability. Most clinic offerings have none of these features.
- Save My Fat banks tissue. It does not treat conditions or enroll patients in trials. Banking preserves optionality for a future that may include compatible FDA-regulated pathways. It does not guarantee access, eligibility, or benefit for any autoimmune application.
- Physician guidance is irreplaceable. No patient should make banking, trial enrollment, or treatment decisions about an autoimmune condition based on this educational article alone. A treating physician who understands the patient’s full clinical history is essential to evaluating any of these options.
Learn More
The following resources on this site provide additional educational context for patients and providers researching the regenerative medicine landscape.
Save My Fat helps individuals preserve their own adipose tissue through validated cryopreservation protocols for potential future opportunities that may arise as regenerative medicine science and FDA regulations evolve. Banking tissue does not guarantee eligibility, access, or clinical benefit from any future therapy or medical program. Save My Fat does not provide FDA-approved treatments or cures.
- What Are Adipose-Derived Stem Cells? A Patient’s Guide provides foundational context on what ADSCs are and how they are identified.
- Emerging Research covers the broader landscape of conditions where adipose-derived cell research is active.
- What Are Clinical Trials for Regenerative Medicine? explains how clinical trials work and what participation involves.
- Adipose Tissue Banking: A Complete Guide covers the full banking process, cryopreservation protocols, and what preservation preserves.
- Expanded Access Programs: How Patients Can Legally Access Investigational Therapies describes the compassionate use framework for patients who cannot enroll in a trial.
- How Stem Cell Banking Works explains the step-by-step banking process.
- For Patients provides an overview of what Save My Fat offers.
- For Providers covers how physicians can offer tissue banking to their patients.
The Reagan-Udall Expanded Access Navigator is a free, independent tool for patients and physicians navigating the expanded access process. It is not affiliated with Save My Fat.
This article is for educational purposes only and does not constitute medical advice. Please consult your licensed healthcare provider regarding all medical decisions.
Last Updated: April 6, 2026
